



AF/GP 1645

PATENT
Docket No. 2026-4205

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Topalian, et al. Group Art Unit: 1645

Serial No. : 08/533,895 Examiner: Weatherspoon, J.

Filed : September 26, 1995

For : MHC CLASS II RESTRICTED MELANOMA ANTIGENS AND
THEIR USE IN THERAPEUTIC METHODS

RECEIVED

CERTIFICATE OF MAILING (37 C.F.R. 1.8(a))

NOV 22 1999

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231
BOX AF

TECH CENTER 1600/2900


Sir:

I hereby certify that the attached 1) Response to Official Action Pursuant to 37 C.F.R. §1.116; and
2) Return postcard (along with any paper(s) referred to as being attached or enclosed) and this Certificate of Mailing
are being deposited with the United States Postal Service on the date shown below with sufficient postage as first-
class mail in an envelope addressed to the: Assistant Commissioner for Patents, BOX AF, Washington, D.C. 20231.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

By:


Dorothy R. Auth
Reg. No. 36,434

Date: November 15, 1999

Mailing Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Telecopier

FORM: CERTMAIL.NY
Rev. 5/27/98



PATENT
Docket No. 2026-4205

11/24/99
Hof (case) T. Gray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Topalian, et al. Group Art unit : 1645
Serial No. : 08/533,895 Examiner : Weatherspoon, J.
Filed : September 26, 1995
For : MHC CLASS II RESTRICTED MELANOMA ANTIGENS
AND THEIR USE IN THERAPEUTIC METHODS

RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.116

Assistant Commissioner for Patents
Washington, D.C. 20231
BOX AF

RECEIVED

NOV 22 1999

Sir:

TECH CENTER 1600/2900

In response to the Official Action mailed August 18, 1999, applicants present the following amendments and remarks.

IN THE CLAIMS

Please amend the claims as follows:

64. (amended) An isolated Major Histocompatibility Complex Class II immunogenic [derivative of tyrosinase] peptide, wherein said [derivative] peptide comprises [at least] a 9 amino acid segment of a sequence selected from the group consisting of QNILLSNAPLGPQFP (Ty 56-70) (SEQ ID NO: 1), NILLSNAPLGPQFP (Ty 57-70) (SEQ ID NO: 2), DYSYLQDSDPDSFQD (Ty 448-462) (SEQ ID NO: 6), YSYLQDSDPDSFQD (Ty 449-462) (SEQ ID NO: 13), and SYLQDSDPDSFQD (Ty 450-462) (SEQ ID NO: 14).

65. (amended) The isolated Major Histocompatibility Complex Class II immunogenic [derivative of tyrosinase of claim 64] peptide, wherein said [derivative] peptide is